WU-NK-101 is under clinical development by Wugen and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WU-NK-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

WU-NK-101 overview

WUNK-101 is under development for the treatment of solid tumors head and neck squamous cell cancer, relapsed and refractory acute myeloid leukemia, metastatic colorectal cancer and melanoma. The therapeutic candidate comprises of natural killer (NK) cells. It is administered through parenteral route. It was also under development for the treatment of relapsed and refractory acute myelocytic leukemia (AML), myelodysplastic syndrome (MDS). It is being developed based on  Moneta platform.

Wugen overview

Wugen is a biotechnology company that develops cell therapies for treatment of hematologic cancer and other solid tumors. The company is investigating its lead product candidate WU-NK-101, an allogenic off-the-shelf NK cell therapy for treatment of acute myeloid leukemia (AML); and monoclonal antibodies (mAb) to treat other solid tumors. It is also developing an off-the shelf fratricide-resistant CAR T cell therapy candidate, WU-CART-007 for treating T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL); and WU-NK-201, a memory NK cell therapy for treatment of solid tumors. The company was funded by Aisling Capital, RiverVest Ventures, Velosity Capital Management, LYZZ Capital, BioGenerator, and others. Wugen is headquartered in St. Louis, Missouri, the US.

For a complete picture of WU-NK-101’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.